Intellex Acquires Expert by Big Village

We're thrilled to announce that Intellex has acquired Expert by Big Village, effective March 22, 2024. This strategic move enhances our capabilities and strengthens our commitment to delivering exceptional solutions to our customers.

Stay tuned for more updates on how this acquisition will benefit our clients and experts.

For inquiries or more information, please contact us at info@intellex.com.

×

Expert Details

Pulmonary Hypertension Drugs, Nitric Oxide and Nitric Oxide Delivery Systems

ID: 731859 Florida, USA

Request Expert

Seasoned Executive with a unique combination of scientific and business expertise in the pharmaceutical industry. Over 18 years of drug development experience (i.v, subcutaneous, inhaled and oral products), 15+ years in Pulmonary Hypertension, including 10 years in years at a profitable NASDAQ traded company, United Therapeutics. Leveraged diverse product development/ commercialization strategies for pulmonary and cardiovascular drugs. Currently leading Phase 2 and Phase 3 development efforts at an advanced development-stage technology company that has developed unique nitric oxide (NO) generation and delivery technology. While President and COO of Lung Rx, Inc., an affiliate company of United Therapeutics, he was responsible for bringing the company's lead product, Tyvaso through Phase 3. He was also responsible for the product pipeline, setting up and managing four concurrent development programs. Expert was the first employee of both United Therapeutics and Lung Rx Inc. and was instrumental to their successful launch. He was a key contributor to the successful development and worldwide commercialization of Remodulin for the treatment of pulmonary arterial hypertension. “ Expert was one of the principal scientific developers of Remodulin, and has also been the key individual responsible for its commercial acceptance in the United States and overseas.” Martine Rothblatt, Chairman/CEO, United Therapeutics. Expert's therapeutic specialties include pulmonary and cardiovascular drugs. His areas of expertise include the following: pulmonary hypertension drugs, nitric oxide and nitric oxide delivery systems, preclinical and clinical research and development, clinical study design, orphan drug development, and inhalation drug development.

Responsible for late stage development of several nitric oxide (NO) delivery platforms for various respiratory diseases. One of the principal scientific developers of Remodulin (treprostinil sodium) for the treatment of pulmonary arterial hypertension. Responsible for bringing the Company’s lead product, Tyvaso successfully through Phase III (primary endpoint met (p<0.0006) – FDA approved. A Key Contributor to the successful development and worldwide commercialization of Remodulin for the treatment of pulmonary arterial hypertension. Successfully set up and managed 5 concurrent development programs TRIUMPH, TRE-MDI, TRE-IPF, a Cell-Mediated Gene Therapy product and Beraprost SR. Solid experience in the development of novel drug/device delivery systems (inhalation, intravenous, and subcutaneous) for the pharmaceutical market. Key Contributor to successful launch of 3 new Companies (including 1 IPO). Led the rapid growth of Lung Rx, Inc. Developed and maintained very strong relationships with national and international thought leaders and professional organizations. Grew Remodulin revenue 40% annually while responsible for Sales and Marketing.

Expert was President of a consulting firm. During this period, he acted as a consultant to GeNO. During this time he was responsible for the following: Provide clinical research leadership, in planning, managing, and executing multiple combination product drug development programs. Develop, Implement, and Manage Toxicology Program. Evaluate partnering/licensing opportunities. Develop and Implement corporate strategy. Assist with Strategic Opportunity Assessment (identify high value, lower risk indications). Develop and execute Company Business Plan. Identify candidates for Scientific Advisory Board. Identify and assess additional product opportunities
Provide scientific consulting for the Pharmaceutical Industry. Subject matter expert in Pulmonary Arterial Hypertension

Education

Year Degree Subject Institution
Year: 1995 Degree: PhD Subject: Microbiology and Immunology Institution: Duke University

Work History

Years Employer Title Department
Years: 2009 to Present Employer: Undisclosed Title: Executive Vice President Global Clinical Affairs Department:
Responsibilities:
Provide clinical research leadership, in planning, managing, and executing multiple combination product drug development programs. Develop, Implement, and Manage Toxicology Program. Evaluate partnering/licensing opportunities. Develop and Implement corporate strategy. Assist with Strategic Opportunity Assessment (identify high value, lower risk indications). Develop and execute Company Business Plan. Identify candidates for Scientific Advisory Board. Identify and assess additional product opportunities
Years Employer Title Department
Years: 1994 to 1997 Employer: Lung Rx, Inc Title: President and COO Department:
Responsibilities:
Responsible for bringing the company’s lead product Viveta (Treprostinil Sodium for Inhalation) from preclinical testing through Phase III Development. Coauthored and reviewed regulatory documents for IND submissions to FDA and EMEA, prepared for and presented at FDA and EMEA meetings. Responsible for the product pipeline and the efficient development of new products. Worked closely with the business development and marketing departments at Lung Rx on clinical trial strategies, overall preparation of the market, and marketing/medical education initiatives. Worked closely with Key Opinion Leaders in the Pulmonary Hypertension community that Co Chaired the TRIUMPH (Treprostinil Sodium for Inhalation) Program Steering Committee.
Provided vision for the Lung Rx organization, building strength and competence for the future, while at the same time having the judgment to prioritize programs/tasks, improve processes and meet timelines. Direct responsibility for a team of 12. Direct reports included Heads of Clinical, Regulatory, R and D and a Chief Medical Officer. Responsible for an annual budget of $10MM. With CEO, established a Scientific Advisory Board.

Career Accomplishments

Associations / Societies
ATS Member, ISHLT Member, Drug Information Association, North Carolina RNA Society (Steering Committee Member), RNA Society
Awards / Recognition
National Register’sWho’sWho, United Therapeutics Certificate of Excellence (Key Contributor), Recipient of Lung Rx, Inc Excellence Awards, Recipient of (2) Cato Research, Ltd. President’s Excellence Awards, Duke University Program in Cell and Molecular Biology Fellowship
Publications and Patents Summary
He is the co-inventor on five U.S. patents and published numerous articles in scientific journals. Expert has extensive experience in winning IND’s and NDA’s for drugs to address PH indications

Fields of Expertise

Request Expert

Dev Tool:

Request: expert/pulmonary-hypertension-drugs-nitric-oxide-and-nitric-oxide-delivery-systems
Matched Rewrite Rule: expert/([^/]+)(?:/([0-9]+))?/?$
Matched Rewrite Query: experts=pulmonary-hypertension-drugs-nitric-oxide-and-nitric-oxide-delivery-systems&page=
Loaded Template: single-experts.php